[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558393":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":17,"responsibleParty":33,"collaborators":7,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":37,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":7,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},{"fullName":5,"class":6},"University Hospital, Brest","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Sarah BOUEE","CONTACT","02 98 22 39 70","sarah.bouee@chu-brest.fr",{"name":15,"role":11,"phone":7,"phoneExt":7,"email":16},"Anne-Solenn JACAMON","anne-solenn.jacamon@chu-brest.fr",[18],{"facility":19,"status":20,"city":21,"state":7,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"CHRU de Brest","RECRUITING","Brest","29609","France","FR",{"type":26,"coordinates":27},"Point",[28,29],-4.48628,48.39029,{"lat":29,"lon":28},[32],{"name":10,"role":11,"phone":7,"phoneExt":7,"email":13},{"type":34,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100558393","impact-of-human-papillomavirus-carriage-on-ivficsi-results-hpv-amp-100558393",false,"NCT06550531","Impact of Human Papillomavirus Carriage on IVF\u002FICSI Results (HPV AMP)","Impact of Human Papillomavirus Carriage on IVF\u002FICSI Results at Brest University Hospital","HPV-AMP","Inclusion Criteria:\n\n* all etiology of infertility AMH \\> ou = à 1.1 ng\u002Fml First ou second protocol of IVF between 25 years and 37 years and 11 months\n\nExclusion Criteria:\n\nAge \\\u003C 25 y Age \\> ou = 38 y AMH \\\u003C 1.1 ng\u002Fml patient under juridic protection rejection of participation","FEMALE","25 Years","38 Years",{"count":47,"type":48},618,"ESTIMATED","OBSERVATIONAL","The prevalence of the papilloma virus in the general population is 12%. This virus is known to impair male fertility but its impact on female infertility remains uncertain. This is a public health problem since there is a vaccination protocol. Demonstrating the impact of the human papillomavirus on fertility would be an argument in favor of vaccination.",[52,53],"Human Papilloma Virus","Infertility, Female","2024-08-09",{"date":56,"type":57},"2024-08-13","ACTUAL",{"date":59,"type":57},"2022-02-04",{"date":61,"type":48},"2026-02-04",{"name":5,"class":6},1]